THU0012 Elevated Risk of Chronic Obstructive Pulmonary Disease in Systemic Lupus Erythematosus: A Population-Based Study: Table 1.
Authors: M. Yurkovich, M. Sadatsafavi, E.C. Sayre, J. Esdaile, A. Avina-Zubieta
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Chronic obstructive pulmonary disease (COPD) has been recently recognized as an inflammatory disease. A recent Swedish hospital-based study (1) found an increased risk of COPD in patients with a number of autoimmune conditions including systemic lupus erythematosus (SLE). We wonder if the risk is also present in SLE patients from the general population. <h3>Objectives</h3> To assess the future risk of <i>newly recorded COPD cases</i> among <i>incident SLE cases</i> compared to controls from the general population using physician billing and hospitalization data that covers the entire province of British Columbia (BC), Canada. <h3>Methods</h3> Our data includes all health professionals and hospital visits covered by the comprehensive provincial medical services plan (1990-2010) and all dispensed medication (1996-2010), for all BC residents. We conducted a retrospective matched cohort (1996-2010) study among patients satisfying at least one of the following validated criteria: a) One diagnostic code for SLE (ICD-9-CM =710.0) on at least two visits within a two-year period by a non-rheumatologist physician; b) One ICD-9 code by a rheumatologist or from hospitalization; c) absence of a prior SLE diagnosis between 1990 and 1995. Ten controls matched by birth year, sex and calendar year of exposure were randomly selected from the general population for each case. Outcome: we used validated criteria to define COPD (first ICD-9-CM: 491, 492, 496, 493.2, or ICD-10-CM J43 or J44) from hospitals or death certificates. We estimated relative risks (RRs) by comparing SLE cases with age-, sex- and entry-time-matched comparison cohorts, adjusting for confounders. Sensitivity analyses were conducted to assess for unmeasured confounders. <h3>Results</h3> Among 4486 individuals with incident SLE, 96 developed COPD (incidence rate =4.96 per 1,000 person years) (see table). The age-, sex- and entry-time matched RRs were significantly increased in the SLE cohort when compared with controls (RR 2.31, 95% CI 1.83-2.89). After adjusting for covariates the results remained statistically significant. The risk of developing COPD was highest within the first year following the diagnosis of SLE, decreasing over time and remaining significant up to 4 years after diagnosis. Our results remained statistically significant after adjusting for the potential impact of an unmeasured confounder (adjusted RRs ranging between 1.58–1.98 in all sensitivity analyses). <h3>Conclusions</h3> This is the first general population-based study indicating a two-fold increased risk of COPD in patients with SLE. The risk of developing COPD was highest within the first year, declining thereafter, suggesting the potential pathogenic role of inflammation in the development of COPD. <h3>References</h3> Hemminki K, Liu X, Ji J, Sundquist K, Sundquist J. Subsequent COPD and lung cancer in patients with autoimmune disease. Eur Respir J 2011 Feb;37(2):463-465. <h3>Acknowledgements</h3> Research funded by an operating grant by the Canadian Arthritis Network/The Arthritis Society and the BC Lupus Society (Grant 10-SRP-IJD-01) <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3912